ClinTec ceo receives Honorary Doctorate

For her contribution to life sciences industry

Dr Rabinder Buttar has been awarded a Doctorate of the University (DUniv) by the University of the West of Scotland.

This honorary doctorate was awarded in recognition of Dr Buttar’s contribution to the life sciences Industry over 20 years and for the foundation and development of ClinTec International.

Professor Seamus McDaid, principal and vice chancellor of the University of the West of Scotland, said: ‘We are delighted to award Dr Buttar with an Honorary Doctorate. As chief executive of ClinTec International, she is one of the country’s most important business leaders, making a hugely important contribution to the Scottish economy.’

At the graduation ceremony, which took place in Paisley, Dr Buttar said: ‘The University has created an exceptional pool of local and international graduates and I am honoured to come back here after 20 years and accept this degree. These graduates here today have successfully completed one chapter of their lives and as they open the next one their learning should never stop.

‘In the current challenging times, graduates should seek local as well as global opportunities, look to do something they feel passionate about, be even more determined than ever before to succeed and then further success will be in their hands. The University and its excellent staff have prepared them well for the challenges that lie ahead.

‘I feel honoured and privileged to join the Court and Senate today in recognising and celebrating in some of Scotland’s academic achievements.’

Dr Buttar has also been named as the Ernst & Young Entrepreneur of the Year for Scotland and the Institute of Directors’ Regional Director of the Year for the West of Scotland.

You may also like

Research & Development

ClinTec expands into China, Singapore and Thailand

Increases presence in emerging markets
Finance

Pharmaceutical firms win Queen’s Awards for Enterprise

Eight firms are lauded for their success in innovation and international trade
Finance

European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health

From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Finance

From pilots to production: what 2026 could mean for pharma

This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies

Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Subscribe now